Literature DB >> 18289002

Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance.

Hongyu Yuan1, Xun Li, Jifeng Wu, Jinpei Li, Xianjun Qu, Wenfang Xu, Wei Tang.   

Abstract

Cancer patients who receive chemotherapy often experience intrinsic or acquired resistance to a broad spectrum of chemotherapeutic agents. The phenomenon, termed multidrug resistance (MDR), is often associated with the over-expression of P-glycoprotein, a transmembrane protein pump, which can enhance efflux of a various chemicals structurally unrelated at the expense of ATP depletion, resulting in decrease of the intracellular cytotoxic drug accumulation. The MDR has been a big threaten to the human health and the war fight for it continues. Although several other mechanisms for MDR are elucidated in recent years, considerable efforts attempting to inverse MDR are involved in exploring P-glycoprotein modulators and suppressing P-glycoprotein expression. In this review, we will report on the recent advances in various strategies for overcoming or circumventing MDR mediated by P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289002     DOI: 10.2174/092986708783503258

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  18 in total

Review 1.  Nanomedicine therapeutic approaches to overcome cancer drug resistance.

Authors:  Janet L Markman; Arthur Rekechenetskiy; Eggehard Holler; Julia Y Ljubimova
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

Review 2.  Bacterial gene amplification: implications for the evolution of antibiotic resistance.

Authors:  Linus Sandegren; Dan I Andersson
Journal:  Nat Rev Microbiol       Date:  2009-08       Impact factor: 60.633

3.  An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.

Authors:  Jianqin Lu; Wenchen Zhao; Hao Liu; Rebecca Marquez; Yixian Huang; Yifei Zhang; Jiang Li; Wen Xie; Raman Venkataramanan; Liang Xu; Song Li
Journal:  J Control Release       Date:  2014-10-24       Impact factor: 9.776

4.  Combined use of anticancer drugs and an inhibitor of multiple drug resistance-associated protein-1 increases sensitivity and decreases survival of glioblastoma multiforme cells in vitro.

Authors:  Lilia Peigñan; Wallys Garrido; Rodrigo Segura; Rómulo Melo; David Rojas; Juan Guillermo Cárcamo; Rody San Martín; Claudia Quezada
Journal:  Neurochem Res       Date:  2011-05-05       Impact factor: 3.996

5.  MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies.

Authors:  Jun Wang; Baocheng Wang; Jingwang Bi; Kainan Li; Jianshi Di
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

6.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

7.  The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers.

Authors:  Alessandra Cappellini; Francesca Chiarini; Andrea Ognibene; James A McCubrey; Alberto M Martelli
Journal:  Cell Cycle       Date:  2009-05-02       Impact factor: 4.534

8.  Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.

Authors:  Abhalaxmi Singh; Fahima Dilnawaz; Sanjeeb Kumar Sahoo
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

9.  Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis.

Authors:  Yulan Yan; Hongjie Liang; Li Xie; Yu He; Meng Li; Ruolin Li; Shan Li; Xue Qin
Journal:  Tumour Biol       Date:  2013-10-20

10.  The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.

Authors:  Iris Eke; Franziska Leonhardt; Katja Storch; Stephanie Hehlgans; Nils Cordes
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.